Vitamin C Gummy Potency Failures on Amazon; GNC Relaunches in Singapore; FDA Nominee
Substandard vitamin C gummies, with nearly half of tested products failing label claims, highlight persistent quality issues on major e-commerce platforms. Concurrently, GNC plans a Q4 2026 re-entry into Singapore's retail market, while a new FDA Commissioner nominee promises scientific commitment for the US supplement sector.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
A recent investigation by US natural products manufacturer NOW revealed significant quality control failures among vitamin C gummy supplements sold on Amazon. Testing 25 products, NOW found that 12, representing 48% of the sample, contained negligible amounts of vitamin C, falling drastically short of label claims. Some products advertised 1,000 mg per gummy contained less than 2 mg. This marks a recurring issue, with NOW reporting a pattern of substandard products despite consistent communication with Amazon and the FDA over nine years.
This ongoing problem underscores a critical challenge for brand owners: maintaining product integrity and consumer trust within unregulated online marketplaces. The lack of effective enforcement against dishonest marketing, labelling, and testing methods poses a significant threat to legitimate manufacturers who invest in quality and compliance. Brand reputation is increasingly vulnerable to the poor performance of competitor products that appear visually similar but deliver no active ingredient.
In the Southeast Asian market, GNC is set to re-establish a significant retail presence in Singapore, leveraging an exclusive distribution partnership with DFI Retail Group, parent company of health and beauty chain Guardian. This strategy involves both standalone GNC stores offering specialised product ranges and widespread availability within Guardian's extensive online and offline network. Products, including vitamins, minerals, and sports nutrition, are slated for availability from Q4 2026, intensifying competition for shelf space and consumer attention in the region.
Meanwhile, the US supplement industry awaits the Senate confirmation of Dr. Heidi Overton as the next FDA Commissioner. Nominated by President Trump, Dr. Overton is perceived as a 'blank slate' with a noted commitment to scientific principles and expanded access to consumer health products. Industry groups, such as the American Herbal Products Association (AHPA), support her nomination, citing her prior work on CBD policy and a pro-innovation posture that prioritises scientific literature and industry resources.
What this means for United Kingdom
UK brand owners must immediately assess their e-commerce channel strategy, particularly for platforms like Amazon, to differentiate from pervasive low-quality imports. Manufacturers should anticipate increased consumer scrutiny regarding vitamin C potency and prepare for enhanced third-party testing verification. GNC's aggressive re-entry into Singapore signals potential for similar regional market consolidation; UK brands exporting to Southeast Asia should brace for intensified competition and review their distribution models. While the FDA Commissioner nomination directly impacts the US, Dr. Overton's commitment to scientific principles could influence global regulatory dialogues, prompting the MHRA or FSA to consider equivalent, science-backed approaches to supplement oversight, affecting novel ingredient approvals and health claim substantiation.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.